Opinion|Videos|March 28, 2025
Tailoring HS Treatment: The Path to Better Patient Outcomes
Author(s)Jerry Bagel, MD, MS
A panelist discusses how clinicians should systematically adopt evidence-based hidradenitis suppurativa (HS) guidelines while maintaining flexibility to tailor treatments to individual patient needs, severity levels, and comorbidities. This involves regular monitoring of updated recommendations, implementing standardized assessment tools, and considering patient-specific factors such as lifestyle, preferences, and treatment response history to optimize therapeutic outcomes through a personalized medicine approach.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How can clinicians integrate evolving guidelines into practice to enhance patient outcomes?
- How can clinicians balance adherence to guidelines with the need for individualized patient care in HS treatment?
Advertisement
Related to this article
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
Advertisement
Advertisement
Trending on AJMC
1
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
2
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
3
Melatonin Use Linked to Small REM Sleep Reduction in Children
4
FDA Approves Belzutifan-Lenvatinib Combo for Advanced Kidney Cancer
5